Table 1.

Baseline Characteristics of the Eligible Subjects (N=45)

Characteristic
Age, years
Median	17·6
Range	5·4 – 28·7
Interquartile Range	15·3 – 18·6
Sex, N (%)
Male	21 (47%)
Female	24 (53%)
Race, N (%)
Black	8 (18%)
White	31 (69%)
Other or Unknown	6 (13%)
Ethnicity, N (%)
Hispanic	10 (22%)
Non-Hispanic	35 (78%)
Country of Residence, N (%)
Canada	2 (4%)
USA	43 (96%)
Disease Status at enrollment, N (%)
Primary refractory (i.e. no prior complete response)	29 (64%)
Early relapse < 6 months after initial therapy	9 (20%)
Advance stage (III or IV) with relapse > 6 months after initial therapy	7 (16%)
Performance Status at Enrollment, N (%)
Normal (100%)	21 (47%)
Minor symptoms or restrictions in activity (90%)	19 (42%)
Tires more quickly; some signs or symptoms of disease (80%)	5 (11%)
Stage at start of therapy with Brentuximab vedotin + gemcitabine
IA, IIA, IIIA	19 (42%)
IIB, IIIB	9 (20%)
IVA, IVB	17 (38%)